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http://dxObjective: The impact of paravalvular aortic regurgitation (PAR) on hemodynamic performance after transcath-
eter aortic valve implantation (TAVI) remains disputable. Common parameters such as the diastolic blood pres-
sure or the blood pressure amplitude do not provide reproducible results. The aim of our study was to evaluate
the impact of PAR on hemodynamics and outcome using the relative amplitude index (RAI).
Methods: PARwas prospectively evaluated by echocardiography before discharge in 110 patients. The RAI was
calculated according to the formula: RAI ¼ [(Post-TAVI BP amplitude)/(Post-TAVI SBP)  (Pre-TAVI BP
amplitude)/(Pre-TAVI SBP)] 3 100%, where BP is blood pressure and SBP is systolic blood pressure. Corre-
lations of increased RAI with perioperative outcome were investigated and factors influencing mortality were
isolated.
Results: The incidence of moderate and severe PAR after TAVI was 9% and 1%, respectively. Diastolic pres-
sure or post-TAVI amplitude did not correlate to perioperative outcome. RAI increased from 2 when PAR was
<2þ to 7 when PAR was 2þ (P ¼ .006). A cut-off value of RAI 14 was associated with increased periop-
erative mortality (29 vs 5%; P¼ .013) and acute renal injury requiring dialysis (71 vs 18%; P¼ .001). RAI14
was also associated with higher follow-up mortality at 1 year (57 vs 16%; P¼ .007). RAI14 (odds ratio [OR],
3.390; 95% confidence interval [CI], 1.6-7.194; P ¼ .00146), PAR 2þ (OR, 4.717; 95% CI, 1.828-12.195;
P ¼ .00135), and perioperative renal replacement therapy (OR, 12.820; 95% CI, 5.181-31.250; P ¼ .00031)
were found to be independent predictors of mortality at 1 year.
Conclusions: The RAI is a useful tool to predict perioperative and 1-year outcome in patients with PAR after
TAVI. (J Thorac Cardiovasc Surg 2014;147:1021-9)MSupplemental material is available online.
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P(TAVI) is a noninferior therapy compared with standard
AVR in terms of all-cause mortality at 30 days and 1 year.
In this patient cohort, 30-day mortality was low both in
the AVR group (6.5%) and the TAVI group (3.4%)
although early-generation devices were used.2 Both TAVI
and AVR are associated with different periprocedural haz-
ards, such as more frequent major vascular and neurologic
complications with TAVI, as well as more major bleeding
events and atrial fibrillation with surgical AVR. Increased
risk for paravalvular regurgitation (PAR) has been the com-
mon denominator of all TAVI series so far.3 Although there
was no difference at 30 days, 1-year mortality was signifi-
cantly higher in patients with PAR 2þ, regardless of ac-
cess and left ventricular function.4 The finding that PAR
2þ is an independent predictor of midterm to long-term
mortality has also been confirmed from the 2-year data of
the PARTNER (Placement of AoRtic TraNscathetER
Valves) trial.5
To provide increased understanding of the impact of PAR
on hemodynamics after TAVI, the aortic regurgitation in-
dex, defined as the ratio of the gradient between diastolic
pressure in the aorta and the left ventricular end-diastolic
pressure to systolic blood pressure (SBP) has been devel-
oped. This index gives additional prognostic informationdiovascular Surgery c Volume 147, Number 3 1021
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
CT ¼ computed tomography
DBP ¼ diastolic blood pressure
LVEF ¼ left ventricular ejection fraction
OR ¼ odds ratio
PAR ¼ paravalvular aortic regurgitation
RAI ¼ relative amplitude index
ROC ¼ receiver operating characteristics
SBP ¼ systolic blood pressure
TAVI ¼ transcatheter aortic valve implantation
VARC ¼ Valve Academic Research Consortium
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Mto the echocardiography; a value less than 25 is an indepen-
dent predictor of 1-year mortality and is associated with
increased rates of PAR.6 Although this was the first attempt
to establish causality based on hemodynamics between
PAR and long-term outcome after TAVI, the need for a
detailed echocardiographic evaluation or even better inva-
sive hemodynamic evaluation is still a limiting factor that
precludes assessment and treatment in the postoperative
period.
We therefore developed an index based on preoperative
and post-TAVI blood pressure measurements based on the
hypothesis that blood pressure amplitude increases in the
presence of PAR.7 However, preoperative blood pressure
amplitude should be taken into consideration because it
may be associated with preexisting regurgitation of the ste-
notic valve8 or with the loss of the windkessel function and
elasticity of the aortic wall in patients with severe
atherosclerosis.9
The aim of our study was to provide a simple, easy to
measure, and reproducible tool to evaluate the impact of
PAR on perioperative and midterm outcome after TAVI us-
ing simple blood pressure measurements before and after
the procedure and taking blood pressure amplitude into
consideration.METHODS
Patients
One-hundred nineteen consecutive patients with a high-grade aortic ste-
nosis underwent TAVI between March 2008 and December 2012 and were
analyzed retrospectively. The study was approved by the local Ethical
Committee and each patient gave informed consent.
Aortic stenosis was diagnosed by transthoracic echocardiography. Indi-
cations for surgery were based on the transthoracic echocardiography re-
sults and symptoms. A preoperative computed tomography (CT) scan
with 128-slice, high-pitch, dual-source, prospective CT angiography was
performed for preoperative evaluation.
A previous cardiac intervention was noted in 51 patients (43%). Almost
one-third of the patients (n ¼ 32, 27%) had previous cardiac surgery at a
median of 10 years before TAVI (range, 5 to 19 years). These previous1022 The Journal of Thoracic and Cardiovascular Surprocedures included aortic valve surgery (n ¼ 2), mitral valve surgery
(n ¼ 2), aortic and tricuspid valve surgery (n ¼ 1), and bypass surgery
(n¼ 27). In addition, percutaneous coronary interventions were performed
in 23 patients (20%) at a median of 2 years before TAVI. In 5 patients
(4%), a previous balloon valvuloplasty was performed at a median of 7
months before TAVI.
Perioperative complications, such as mortality, cardiac, lung, cerebro-
vascular, or renal dysfunction, implantation of a second valve caused by
prosthesis migration and PAR, as well as long-term outcome regarding sur-
vival and late prosthesis dysfunction were analyzed according to the Valve
Academic Research Consortium (VARC)-2 criteria.10
Perioperative mortality was defined as mortality within 30 days. Long-
term mortality was defined as death thereafter. The follow-up period was 2
to 1721 days (median, 377 days) and was 100% complete including clin-
ical and echocardiographic examinations. Examination visits were stan-
dardized at 30 days, 6 months, 12 months, and thereafter yearly after
TAVI. Procedural outcome was analyzed according to the VARC-2 criteria
regarding device success, early safety, clinical efficacy, and time-related
valve safety. Renal impairment was analyzed according to the Acute Kid-
ney Injury Network system.10
PAR was prospectively evaluated by echocardiography during TAVI
and before discharge. Echocardiographic evaluation was based on periop-
erative transesophageal or intracardiac echocardiography according to the
recommendations of the European Association of Echocardiography.11
The relative amplitude index (RAI) was retrospectively calculated accord-
ing to the following formula:
RAI ¼

Post-TAVI BP amplitude
Post-TAVI SBP
 Pre-TAVI BP amplitude
Pre-TAVI SBP

3100%
where BP is blood pressure and SBP is systolic blood pressure.
In our study, blood pressure was measured intraoperatively using arte-
rial pressure. Preimplantation values were the average of at least 3 values
between skin cut and balloon valvuloplasty and postimplantation values
were the average of at least 3 values between valve implantation and
skin suture. To evaluate the potential effect of continuous invasive blood
pressure measurements on RAI, we also analyzed noninvasive blood pres-
sure measurements in 88 patients. These included preoperative measure-
ments at admission and the median of 5 postoperative measurements
after extubation, without inotropes, and in a comparable volume status until
discharge. All measurements included were performed under stable hemo-
dynamic and rhythm conditions.
The formula was created and calculated by using intraoperative blood
pressure measurements, which were collected independently from the clin-
ical outcome. In addition to the collection of intraoperative blood pressure
data, the clinical outcome and follow-up data were collected separately by
3 different investigators after Ethical Committee approval. The statistical
analysis was undertaken after completion of the data set. Therefore, there
is no observer bias at any time in the study and the results of the RAI cal-
culations could not be influenced by the clinical data.
Surgical Technique
All TAVI procedures were evaluated, indicated, and performed by a
heart team. During TAVI, 1 experienced cardioanesthesiologist and 1
perfusionist were always present in the operating room. Apart from the first
9 procedures, which were performed in a catheterization laboratory, all
other interventions took place in the cardiac operating room with cardio-
pulmonary bypass (CPB) on standby using a new generation mobile
C-arm (OEC 9800, Ziehm RFD, Philips Veradius, Siemens Arcadis).
Each patient underwent general anesthesia and was set up with an arterial
blood pressure line, intracardial echocardiography or transesophageal
echocardiography, and a submerged temporal pacemaker. The surgical
approach for TAVI was always performed by a cardiac surgeon as planned
after a preoperative CT scan: transfemoral approach with a 3 to 4 cm inci-
sion in the groin and femoral artery preparation; transapical approach withgery c March 2014
TABLE 1. Patient demographics, preoperative risk factors, and access
site
Number or value
(N ¼ 110) Range or%
Age (y) 83 58-97
Sex (M/F) 51/59 46/54
Body mass index (kg/m2) 25 18-37
EuroSCORE II 10 2-40
Left ventricular ejection fraction (%) 50 11-73
Arterial hypertension 101 92
Atrial fibrillation 39 36
Myocardial infarction 9 8
Pulmonary hypertension 35 32
Chronic obstructive pulmonary disease 24 22
Cerebrovascular disease 31 28
Stroke 16 15
Renal impairment 9 8
Previous dialysis 3 3
Heinz et al Perioperative Managementa 5 to 6 cm incision in the fifth or sixth intercostal space as an anterolateral
thoracotomy; transaxillary approach with a 3 to 4 cm incision below the
clavicle; and transaortal approach with a 5 to 6 cm incision and upper hemi-
sternotomy in the second intercostal space.
Statistical Analysis
Continuous variables were expressed as the median and range, categor-
ical variables as percentages. Continuous variables were analyzed by the
Mann-Whitney U test, categorical variables were tested for differences us-
ing the c2 test. Estimates of survival and the incidence of valve-related
complications were calculated using Kaplan-Meier graphs and statistical
differences were analyzed by the Wilcoxon method. Statistical analysis
was performed using SPSS statistical software 19.0 (SPSS Inc, Chicago,
Ill). The cut-off value for RAI, over which perioperative mortality reached
statistical significance, was evaluated by receiver operating characteristics
(ROC) analysis (Figure E1). Patients with an RAI above the cut-off value
were then compared with patients with an RAI below the cut-off value in
terms of perioperative and postoperative outcome. Dependent and indepen-
dent factors for perioperative and follow-up mortality were isolated using
Cox regression analysis.Previous cardiac surgery 29 26
Previous percutaneous coronary
intervention
24 22
Access site
Transfemoral 49 45
Transapical 48 44
Transaxillar 5 4
Transaortic 8 7
Balloon expanded 104 95
Self-expanded 6 5
Follow-up period (d) 377 2-1721RESULTS
Of the 119 patients whowere initially included for intent-
to-treat analysis, 110 underwent the procedure as planned
and were included in our study. The reasons for exclusion
were uncompleted TAVI because of narrow femoral vessels
(only balloon valvuloplasty performed in 2 patients), con-
version to conventional AVR in 5 patients (ventricular
perforation in 2 patient, annulus rupture in 1 patient, valve
migration in the left ventricular outflow tract in 1 patient,
and irreversible crash of an old generation mobile C-arm
in 1 patient), and lost to follow-up (2 patients). Patients
with uncompleted TAVI and conversion to conventional
AVR were excluded because no relevant postprocedural
RAI could be calculated. Patients lost to follow-up were
also excluded to avoid incomplete reporting of the results.
The patients included had a median age of 83 years
(range, 58-97 years), 51 were male (46%), and the median
EuroSCORE II was 10 (range, 2-40). Demographics, preop-
erative risk factors, and details on access site are presented
in Table 1.P
MIntraoperative Complications
Besides conversion to AVR, an unplanned use of CPB
was necessary in a further 6 patients. In 1 patient, conver-
sion to full sternotomy was needed because of apex perfo-
ration. In 2 patients, valve malposition led to a second
valve implantation. In 3 patients, the TAVI procedure was
a valve-in-valve deployment. Therewas no case of coronary
obstruction, ventricular septum perforation, or mitral valve
damage or dysfunction. The device success rate according
to the VARC-2 criteria10 was 98% (n ¼ 108).Perioperative Results
The perioperative mortality was 6% (n ¼ 7). These pa-
tients died of multiorgan failure and low output syndromeThe Journal of Thoracic and Car(n ¼ 5), respiratory failure (n ¼ 1), and terminal renal fail-
ure (n ¼ 1) between postoperative day 2 and 24. Perioper-
ative results are summarized in Table 2. Intensive care unit
stay was 24 hours (range, 2-1027 hours). Early safety and
clinical efficacy according to the VARC-2 criteria were
fulfilled by 78 patients (71%) and 101 patients (92%),
respectively. PAR 2þ was detected in 11 patients
(10%). None of the patients included in the series had
relevant central regurgitation. This was confirmed in 3
different projections using echocardiography. An RAI
value between 13 and þ23% (mean þ3%) was calcu-
lated after taking into consideration perioperative blood
pressure measurements.
The RAI increased from 2 (32 to þ23%) when PAR
was <2þ to 7 (3 to þ17%) when PAR was 2þ
(P ¼ .006) (Figure E2, A). In contrast, neither the absolute
blood pressure amplitude (Figure E2, B) nor the absolute
diastolic pressure amplitude (Figure E2, C) differed in pa-
tients with PAR<2þ versus patients with PAR 2þ (65
mm Hg [range, 40-85 mm Hg] vs 55 mm Hg [range, 30-
75 mm Hg], respectively; P ¼ .932). A cut-off value for
the RAI of 14 was calculated by ROC analysis (P ¼ .035)
and patients with an RAI 14 had increased perioperative
(29 vs 5%; P ¼ .013) and long-term mortality (71% vs
25%; P ¼ .007) compared with patients with an RAI<14diovascular Surgery c Volume 147, Number 3 1023
TABLE 2. Perioperative and midterm results after transcatheter aortic valve implantation stratified by RAI
All patients
(N ¼ 110), n (%)
Perioperative results Follow-up results at 1 y
RAI<14
(n ¼ 103), n (%)
RAI 14
(n ¼ 7), n (%)
P
value
RAI<14
(n ¼ 103), n (%)
RAI 14
(n ¼ 7), n (%)
P
value
30-d mortality 7 (6) 5 (5) 2 (29) .013
Overall mortality 30 (27) 16 (16) 4 (57) .007
Reoperation due to bleeding 4 (4)
Major vascular complication 5 (5)
Pacemaker implantation 4 (4)
Paravalvular aortic regurgitation
None or trace 61 (56) 59 (57) 2 (29) .067
Mild 38 (35) 35 (34) 3 (43) .633
Moderate 10 (9) 9 (9) 1 (13) .621
Severe 1 (1) 0 (0) 1 (14) <.001
Perioperative respiratory failure 9 (8) 8 (8) 1 (14) .460
Perioperative AKI requiring
hemofiltration
23 (21) 18 (18) 5 (71) .001 3 (3) 1 (20) .06
AKI Stage 1 35 (32) 32 (31) 3 (43) .517
AKI Stage 2 17 (16) 15 (15) 2 (29) .321
AKI Stage 3 9 (8) 7 (7) 2 (29) .101 7 (7) 0 (0) .531
Stroke 2 (2) 0 (0) .710 5 (5) 0 (0) .601
Myocardial infarction 1 (1) 0 0 1 (1) 0 (0) .819
Device success 108 (98) 2 (2) 0 (0) .710
Valve deterioration
Endocarditis 1 (1) 1 (1) 0 (0) .819
Dysfunction 10 (9) 8 (8) 2 (29) .068
Degeneration 0 0 0
Rehospitalization for cardiac reasons 17 (16) 15 (15) 2 (29) .147
RAI, Relative amplitude index; AKI, acute kidney injury.
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M(Table 2). All common preoperative risk factors showed no
significant difference between RAI<14 and RAI 14.
To evaluate the effect of blood pressure measurements on
RAI, we retrospectively compared invasive and noninvasive
techniques. We found a significant correlation (Spearman
rho ¼ 0.673, P ¼ .031) between the intraoperative RAI
based on invasive blood pressure measurements and the
postoperative RAI based on noninvasive measurements.
Similar to the invasive measurements, there was a higher
incidence of perioperative (P ¼ .024) and 1-year mortality
(P ¼ .014) among patients with RAI 14 measured by
noninvasive means. We also performed additional calcula-
tions to examine the effect of postoperative RAI based on
noninvasive measurements on 30-day and follow-up mor-
tality. There was a significantly higher incidence of both
perioperative and follow-up mortality in patients with
RAI>14 (data not shown).
RAI 14 was a significant predictor for 30-day (odds ra-
tio [OR], 7.840; 95% confidence interval [CI], 1.208-
50.863; P ¼ .013) and follow-up mortality (OR, 7.8; 95%
CI, 1.424-42.721; P ¼ .007) in the univariate analysis
(Table 3). PAR 2þ was not significant for perioperative
mortality (OR, 4.178; 95% CI, 0.707-24.692; P ¼ .091)
but was significant for follow-up mortality (OR, 7.783;
95% CI, 1.554-21.518; P ¼ .004). RAI (OR, 3.390; 95%1024 The Journal of Thoracic and Cardiovascular SurCI, 1.6-7.194; P ¼ .00146), PAR 2þ (OR, 4.717; 95%
CI, 1.828-12.195; P ¼ .00135), and perioperative renal
replacement therapy (OR, 12.820; 95% CI, 5.181-31.250;
P ¼ .00031) were independent predictors of mortality in
the follow-up period.
Long-Term Results
Survival at 1, 3, and 4 years was 82%, 58%, and 40%,
respectively (Figure 1). At a median of 377 days of
follow-up, 30 patients (27%) died. Complications in the
follow-up period occurred in 26 patients (Table 2). Periop-
erative and long-term results stratified by mortality and RAI
are shown in Table 3 and Figure 2. There was no valve
thrombosis or reoperation of the aortic valve after TAVI.
Time-related valve safety during follow-up according to
the VARC-2 criteria was fulfilled by 95 patients (86%).
DISCUSSION
In this study, we aimed for the first time to evaluate an
easy to measure, reproducible, and inexpensive index based
on blood pressure amplitude as a predictive factor for peri-
operative and midterm mortality. In most cases with moder-
ate or severe PAR, angiographic or, even better,
echocardiographic evaluation is easy to perform with reli-
able results. In our hands, most PAR is still mild or mildgery c March 2014
FIGURE 1. Kaplan-Meier graph for survival in the whole study popula-
tion.
Heinz et al Perioperative Managementto moderate. It is therefore obvious that an additional crite-
rion is needed to identify patients who would benefit from
postdilation and to what extent this dilation should be per-
formed to avoid dilatation-associated complications (embo-
lism, aortic rupture, and aortic dissection). Taking into
consideration these points, we consider RAI to be a comple-
mentary index to the echocardiographic or angiographic
evaluation of PAR.FIGURE 2. Kaplan-Meier graph for survival for RAI<14 versus 14.
RAI, Relative amplitude index.
The Journal of Thoracic and Car
P
MOur results underline the major impact of PAR on hemo-
dynamics after transcatheter treatment of severe aortic ste-
nosis. The results show that hemodynamic alterations have
an impact on blood pressure amplitude and on the RAI. This
index is defined as the difference in the ratio of preoperative
and postoperative blood pressure amplitude divided by the
concomitant SBP. In our hands, RAI has been found to
correlate with the presence of hemodynamically relevant
PAR (PAR 2þ) and with 30-day and midterm mortality
after TAVI. RAI levels 14 have also been shown to be
an independent predictor of 1-year mortality. These findings
give this easy to calculate and reproducible index increasing
importance for predicting outcome after TAVI.
With regard to the clinical outcome of this series, we
demonstrated equivalent results to those reported in major
TAVI registries (German Aortic Valve Registry [GARY]
and registries in the United Kingdom, Italy, and France).
Our patient series was mainly treated with balloon-
expandable valves and the results were in line with the
existing literature regarding perioperative and long-term
mortality, incidence of stroke, need for pacemaker implan-
tation, and myocardial infarction.12-14 There is a slight
discrepancy in the literature concerning the effect of the
valve implanted on the incidence of PAR. The UK and
German registries in contrast to the French and Italian
registries demonstrated an increased rate of PAR in self-
expandable valves. We observed an incidence of clinically
relevant PAR of 10%, which is in line with the results re-
ported for balloon-expandable valves. Also the results of
valve-in-valve procedures were highly satisfactory in our
study with a procedural success rate of 100% and low
PAR, making this a safe and feasible alternative to treat
high-risk patients with failing bioprostheses.15
The impact of PAR as well as the detailed pathophysio-
logic alterations associated with the sudden change from
pressure to volume overload is still under investigation.8
A possible approach for chronic AVR could be the correla-
tion between the decrease in diastolic blood pressure (DBP)
and the increase in SBP.16 On the contrary, in acute aortic
regurgitation the left ventricle fails to increase the stroke
volume, which results in increased left ventricular end-
diastolic pressure and consequently pulmonary edema and
decreased SBP.8 The combination of decreased DBP as a
result of aortic regurgitation and decreased SBP as a conse-
quence of acute volume overload induces end-organ dam-
age including myocardial and renal ischemia, as well as
pulmonary complications. According to our results, the
evaluation of postoperative DBP or blood pressure ampli-
tude was not associated with PAR or with periprocedural
or long-term complications. The main reason was that pa-
tients with preexisting low DBP or high blood pressure
amplitude could not be filtered out. Therefore, we devel-
oped an index that takes preoperative and postoperative
blood pressure amplitudes into consideration to identifydiovascular Surgery c Volume 147, Number 3 1025
TABLE 3. Perioperative and midterm results after TAVI stratified by mortality
Perioperative results Follow-up results at 1-y
OR 95% CI 95% CI P value OR 95% CI 95% CI P value
Balloon/self-expandable 1.072 1.018 1.129 .511 0.167 0.029 0.963 .026
TAVI
Transapical 3.488 0.646 18.828 .125 1.424 0.613 3.308 .410
Transfemoral 0.191 0.022 1.643 .096 0.526 0.219 1.263 .147
Transaxillary 0.993 0.887 0.982 .551 12.154 1.3 113.671 .007
Transaortic 2.286 0.240 21.725 .460 0.360 0.042 3.053 .330
Unplanned use of cardiopulmonary bypass 4.125 0.397 42.871 .201 1.833 0.291 11.552 .513
Valve-in-valve deployment 0.933 0.889 0.983 .647 0.720 0.639 0.810 .282
RAI 14 7.840 1.208 50.863 .013 7.8 1.424 42.721 .007
Major vascular complication 0.993 0.887 0.982 .551 0.655 0.070 6.109 .709
Stroke 0.935 0.890 0.983 .710 0.259 0.188 0.357 .02
Perioperative arteriovenous block stage III (new pacemaker) 0.934 0.888 0.982 .595 2.786 0.374 20.728 .298
Stage 1 AKI 1.664 0.352 7.872 .517 1.652 0.688 3.969 .259
Stage 2 AKI 2.347 0.417 13.221 .321 1.133 0.363 3.542 .829
Stage 3 AKI 5.486 0.897 33.536 .052 3.8 0.946 15.261 .057
Perioperative renal replacement therapy 1.438 1.097 1.884 <.0001 6.903 2.545 18.721 .000047
Perioperative respiratory failure 26.133 4.560 149.779 <.0001 3.800 1.146 15.261 .047
Paravalvular aortic regurgitation
None or trace 1.076 0.229 5.052 .926 0.943 0.378 2.349 .899
Mild 0.297 0.034 2.565 .244 0.375 0.138 1.020 .149
Moderate 4.75 0.792 28.494 .064 4.750 1.237 18.246 .115
Severe 0.936 0.891 0.983 .793 0.266 0.195 0.363 .101
2þ 4.178 0.707 24.692 .091 5.783 1.554 21.518 .004
sPAP>60 mm Hg 15.310 1.765 132.773 .002 3.669 1.517 8.872 .003
Previous cardiac surgery 0.446 0.051 3.875 .454 0.467 0.160 1.364 .158
Previous valvuloplasty 4.125 0.397 42.871 .201 1.833 0.291 11.552 .513
Atrial fibrillation 2.590 0.549 12.223 .215 1.925 0.815 4.545 .132
Chronic obstructive pulmonary disease 1.473 0.267 8.112 .655 1.455 0.547 3.865 .451
Chronic venous insufficiency 1.021 0.187 5.560 .981 0.901 0.351 2.314 .829
Mitral regurgitation 2þ 1.185 0.217 6.478 .845 2.146 0.859 5.360 .098
Smoking 0.928 0.878 0.981 .317 1.8 0.539 6.015 .335
Hyperlipidemia 0.253 0.053 1.207 .067 0.538 0.218 1.328 .176
Arterial hypertension 0.505 0.054 4.730 .543 0.433 0.108 1.737 .227
Body mass index 30 kg/m2 1.060 0.118 1.474 .959 1.4 0.436 4.496 .571
Diabetes 0.911 0.851 0.976 .087 1.737 0.707 4.266 .226
Cerebrovascular accident 0.921 0.867 0.979 .184 0.570 0.175 1.858 .347
Previous stroke 0.926 0.874 0.980 .259 0.872 0.258 2.948 .825
Peripheral vascular disease 0.978 0.110 8.707 .984 1.750 0.575 5.327 .320
Creatinine 2 mg/dL 1.979 0.211 18.528 .543 3.8 0.946 15.261 .057
Dialysis 0.935 0.889 0.983 .647 5.643 0.492 64.667 .120
History of cancer 0.914 0.854 0.977 .102 0.467 0.160 1.364 .158
Statistically significant results (P<.05) are in bold. TAVI, Transcatheter aortic valve implantation; OR, odds ratio; CI, confidence interval; RAI, relative amplitude index; AKI,
acute kidney injury; sPAP, systolic pulmonary arterial hypertension.
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Mthe patients who are more at risk for PAR-associated organ
damage. One explanation could be that patients with preex-
isting aortic regurgitation in addition to aortic stenosis are
more likely to compensate for the volume overload result-
ing from PAR due to the increased left ventricular end-
diastolic volume and myocardial hypertrophy.17
Another possible approach could be a high preexisting
blood pressure amplitude due to the occurrence of vessel
wall stiffness associated with atherosclerotic processes.
The hypothesis that large artery stiffening is related to a1026 The Journal of Thoracic and Cardiovascular Surdecreased DBP has been postulated in older studies.18 A
high degree of arterial stiffness was found to correlate
with increased aortic atherosclerosis and worse clinical
outcome in elderly patients.9 This extends to a significant
association between aortic root/valve calcification scores
and the degree of PAR.19
Our results confirm the findings of previous investigators
that PAR 2þ is associated with increased mortal-
ity.4,6,20,21 According to the GARY investigators, PAR
2þ was an independent predictor for perioperativegery c March 2014
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Mmortality after TAVI.22 The results of the Italian registry re-
vealed that previous stroke, previous acute pulmonary
edema, chronic kidney disease, and PAR 2þ were signif-
icant predictors of 1-year mortality.23 In the UK registry, in-
dependent predictors of 1-year mortality were other than
transfemoral route, low left ventricular ejection fraction
(LVEF), chronic obstructive pulmonary disease, and PAR
2þ.24 Even in follow-up results of patients who under-
went conventional surgical AVR, significantly higher mor-
tality rates were observed in those with residual PAR
>1þ.21 Common surgical scores such as EuroSCORE I or
II and Society of Thoracic Surgeons score are considered
to be poor predictors for the outcome after TAVI.25
Similar to PAR2þ, RAI14 was shown to be a signif-
icant independent predictor for long-term mortality in pa-
tients after TAVI. According to our hypothesis, blood
pressure amplitude, and consequently RAI, increase in the
presence of PAR.Moreover, we detected a linear correlation
between the severity of PAR and RAI. This finding is sup-
ported by the results of Sinning and colleagues,6 who
described the aortic regurgitation index, based on the
gradient between DBP and left ventricular end-diastolic
pressure. The investigators of this study found a significant
difference in 1-year mortality and acute renal failure be-
tween patients with low and high aortic regurgitation index.
We also found higher perioperative cardiac and renal com-
plications as possible signs of end-organ failure in patients
with PAR 2þ and RAI 14.
From the observation that most deaths occur within 3
months after TAVI, we aimed to further investigate the
impact of increased RAI as well as PAR 2þ on the
midterm outcome after the procedure. The aortic regurgita-
tion index was found to be an independent predictor of
1-year mortality after TAVI using exclusively self-
expandable valves.6 In our hands, RAI14 was also associ-
ated with a significantly higher midterm mortality. A trend
of higher renal and respiratory failure as well as rehospital-
ization for cardiac reasons but not stroke was observed in
these patients. Not surprisingly, the effect of PAR, and
consequently increased RAI, is more apparent in the
midterm or long-term after TAVI because the long-term con-
sequences of severe aortic regurgitation (such as volume
overload, left ventricular dilatation, reduction of the
LVEF, and endocarditis) become more evident. For this
reason, we consider this index to be an important prognostic
factor for mortality and outcome after TAVI. A closer look
among patients who died reveals that all patients with
both RAI14 and PAR2þ were dead, whereas mortality
rates were higher among patients with RAI14 and no sig-
nificant PAR than for patients with PAR 2þ and normal
RAI. Thus, RAI can discriminate between prognostically
relevant PAR independent from the severity of regurgitation
and regardless of the access route.26Moreover, there are still
some patients without significant PAR but a pathologic RAIThe Journal of Thoracic and Carsuggesting that other factors influencing hemodynamics
may play a role in mortality after TAVI. This is supported
by the fact that 3 of 5 patients with RAI 14 who died
had no PAR. Severe atherosclerosis with increased arterial
stiffness and subsequent low diastolic and mean arterial
pressure may lead to end-organ hypoperfusion and failure
in these patients. Although this is one of the few studies in
the literature correlating hemodynamic alterations in pa-
tients with PAR after TAVI with perioperative and midterm
outcome, it has some limitations. The retrospective design
and the low number of patients with PAR in this monocenter
study may have led to some bias. However, we present a
representative population of TAVI candidates, mainly
including patients treated with balloon-expandable valves,
with 100% complete follow-up.
CONCLUSIONS
Our results demonstrate that RAI is not only a useful tool
to predict the hemodynamic effect of PAR after TAVI but is
also an independent predictor for midterm mortality. The
calculation of this novel index in contrast to preexisting
studies is independent from the availability of cardiac ultra-
sonography or angiography; it is easy to perform (even at the
bedside) and is a reproducible and inexpensivemethod based
on 2 simple bloodmeasurements. RAI can be also calculated
on an outpatient basis and can be used to follow patients with
known PAR. However, the postoperative course of RAI, as
well as its impact on the long-term outcome after TAVI,
and the correlation to the patterns of valvular and annular
calcification27 remain unexplored. Possible changes in the
index as a result of left ventricular adaptation or optimized
medical treatment may be significant factors influencing
outcome and can be addressed in further investigations.
References
1. BonowRO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, FreedMD, et al.
2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the
management of patients with valvular heart disease: a report of theAmerican Col-
lege of Cardiology/American Heart Association Task Force on Practice Guide-
lines (Writing Committee to Revise the 1998 Guidelines for the Management
of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovas-
cular Anesthesiologists, Society for Cardiovascular Angiography and Interven-
tions, and Society of Thoracic Surgeons. Circulation. 2008;118:e523-661.
2. Svensson LG, Tuzcu M, Kapadia S, Blackstone EH, Roselli EE, Gillinov AM,
et al. A comprehensive review of the PARTNER trial. J Thorac Cardiovasc
Surg. 2013;145(3 Suppl):S11-6.
3. Unbehaun A, Pasic M, Dreysse S, Drews T, Kukucka M, Mladenow A, et al.
Transapical aortic valve implantation: incidence and predictors of paravalvular
leakage and transvalvular regurgitation in a series of 358 patients. J Am Coll Car-
diol. 2012;59:211-21.
4. Hayashida K, Lefevre T, Chevalier B, Hovasse T, Romano M, Garot P, et al.
Impact of post-procedural aortic regurgitation on mortality after transcatheter
aortic valve implantation. JACC Cardiovasc Interv. 2012;5:1247-56.
5. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al.
Two-year outcomes after transcatheter or surgical aortic-valve replacement. N
Engl J Med. 2012;366:1686-95.
6. Sinning JM, Hammerstingl C, Vasa-Nicotera M, Adenauer V, Lema
Cachiguango SJ, Scheer AC, et al. Aortic regurgitation index defines severity
of peri-prosthetic regurgitation and predicts outcome in patients after transcath-
eter aortic valve implantation. J Am Coll Cardiol. 2012;59:1134-41.diovascular Surgery c Volume 147, Number 3 1027
Perioperative Management Heinz et al
P
M7. Noble S, Roffi M. Pressure curve measurements during transcatheter aortic valve
implantation: a useful tool to assess the severity of aortic regurgitation. Ann
Thorac Surg. 2013;95:e21.
8. Gotzmann M, Lindstaedt M, M€ugge A. From pressure overload to volume over-
load: aortic regurgitation after transcatheter aortic valve implantation. Am Heart
J. 2012;163:903-11.
9. Witteman JC, Grobbee DE, Valkenburg HA, van Hemert AM, Stijnen T,
Burger H, et al. J-shaped relation between change in diastolic blood pressure
and progression of aortic atherosclerosis. Lancet. 1994;343:504-7.
10. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM,
Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter
aortic valve implantation: the Valve Academic Research Consortium-2
consensus document. J Thorac Cardiovasc Surg. 2013;145:6-23.
11. Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E,
et al. European Association of Echocardiography recommendations for the
assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation
(native valve disease). Eur J Echocardiogr. 2010;11:223-44.
12. Bleiziffer S, Mazzitelli D, Opitz A, Hettich I, Ruge H, Piazza N, et al. Beyond the
short-term: clinical outcome and valve performance 2 years after transcatheter
aortic valve implantation in 227 patients. J Thorac Cardiovasc Surg. 2012;143:
310-7.
13. Conradi L, Seiffert M, Treede H, Silaschi M, Baldus S, Schirmer J, et al. Trans-
catheter aortic valve implantation versus surgical aortic valve replacement: a pro-
pensity score analysis in patients at high surgical risk. J Thorac Cardiovasc Surg.
2012;143:64-71.
14. Wilbring M, Tugtekin SM, Alexiou K, Simonis G, Matschke K, Kappert U.
Transapical transcatheter aortic valve implantation vs conventional aortic valve
replacement in high-risk patients with previous cardiac surgery: a propensity-
score analysis. Eur J Cardiothorac Surg. 2013;44:42-7.
15. Bapat V, Attia R, Redwood S, Hancock J, Wilson K, Young C, et al. Use of trans-
catheter heart valves for a valve-in-valve implantation in patients with degener-
ated aortic bioprosthesis: technical considerations and results. J Thorac
Cardiovasc Surg. 2012;144:1372-9; discussion 1379-80.
16. Bekeredjian R, Grayburn PA. Valvular heart disease: aortic regurgitation. Circu-
lation. 2005;112:125-34.
17. Goldbarg SH, Halperin JL. Aortic regurgitation: disease progression and man-
agement. Nat Clin Pract Cardiovasc Med. 2008;5:269-79.
18. Sleight P. Blood pressures, hearts, and U-shaped curves. Lancet. 1988;1:235.
19. Koos R, Mahnken AH, Dohmen G, Brehmer K, G€unther RW, Autschbach R, et al.
Association of aortic valve calcification severity with the degree of aortic regurgi-
tation after transcatheter aortic valve implantation. Int J Cardiol. 2011;150:142-5.
20. Toggweiler S, Humphries KH, Lee M, Binder RK, Moss RR, Freeman M, et al.
5-year outcome after transcatheter aortic valve implantation. J Am Coll Cardiol.
2013;61:413-9.
21. Sponga S, Perron J, Dagenais F, Mohammadi S, Baillot R, Doyle D, et al. Impact
of residual regurgitation after aortic valve replacement. Eur J Cardiothorac Surg.
2012;42:486-92.
22. Zahn R, Gerckens U, Linke A, Sievert H, Kahlert P, Hambrecht R, et al. Predic-
tors of one-year mortality after transcatheter aortic valve implantation for severe
symptomatic aortic stenosis. Am J Cardiol. 2013;112:272-9.
23. Tamburino C, Capodanno D, Ramondo A, Petronio AS, Ettori F, Santoro G, et al.
Incidence and predictors of early and late mortality after transcatheter aortic
valve implantation in 663 patients with severe aortic stenosis. Circulation.
2011;123:299-308.
24. Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD,
Young CP, et al. Long-term outcomes after transcatheter aortic valve implanta-
tion in high-risk patients with severe aortic stenosis: the U.K. TAVI (United
Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol.
2011;58:2130-8.
25. Barili F, Pacini D, Capo A, Ardemagni E, Pellicciari G, Zanobini M, et al. Reli-
ability of new scores in predicting perioperative mortality after isolated aortic
valve surgery: a comparison with the society of thoracic surgeons score and lo-
gistic EuroSCORE. Ann Thorac Surg. 2013;95:1539-44.
26. Bonaros N, Bartel T, Friedrich G, Mueller S, Feuchtner G, Schachner T, et al.
Transcatheter aortic valve implantation via transaortic access: a bail-out strategy
in unexpectedly inoperable patients. Eur Surg. 2012;44:416-8.
27. Feuchtner G, Plank F, Mueller S, Leipsic J, Schachner T, Mueller L, et al. Predic-
tion of paravalvular regurgitation after transcatheter aortic valve implantation by
computed tomography: value of aortic valve and annular calcification. Ann
Thorac Surg. 2013;96:1574-80.1028 The Journal of Thoracic and Cardiovascular SurDiscussion
DrRakeshM. Suri (Rochester, Minn). I would like to thank the
Association for the privilege of discussing this paper. By way of
disclosure, I am the principal investigator for the FDA IDE trial
of the Sorin PERCEVAL valve, but I have no disclosures related
to this discussion. I would like to thank Dr Bonaros for sending
me a copy of his manuscript in advance.
Dr Bonaros and his colleagues present a study aiming to eval-
uate the impact of paravalvular leakage, PVL, on hemodynamics
and outcome using the relative amplitude index. The authors
used ROC analysis to determine that a cut-off point of 14 was asso-
ciated with increased perioperative respiratory failure, acute renal
injury, mortality, and cardiac and renal complications. Interest-
ingly, however, amplitude index and PVL were both found to be
independent predictors of mortality at one year.
This is an innovative attempt at developing a simplified
hemodynamic parameter to ascertain the degree of peripros-
thetic regurgitation after TAVR. We recall the recently pub-
lished Sinning aortic regurgitation index that Dr Bonaros has
alluded to today, calculated according to the formula he also
described.
That study, too, utilized ROC analysis delineating an index of
less than 25 as important in predicting increased one-year mortal-
ity compared with those with an index of greater than 25. The
Sinning index also provided additional prognostic information
beyond echocardiographically assessed severity of PVL.
Now, both of these mathematical formulae are so-called simple
bedside assessments of PVL and may potentially facilitate deci-
sions regarding the need for further balloon dilation of the pros-
thesis or perhaps TAVR-in-TAVR procedures to ameliorate
periprosthetic leak in the operating room.
However, the numbers are small in both studies, sowe are mind-
ful of the fact that this may limit the statistical robustness of the
proposed relationship between the relative amplitude index
(RAI) and the aforementioned end points.
Three simple questions, Dr Bonaros. The first, you alluded to
this briefly, but can you please describe what you feel is the true
benefit of this new index versus the Sinning index?
Second, the audience would benefit from a description of how
your method might be influenced by alterations in ventricular
load, and particularly, how it might be affected by either a hyper-
trophied ventricle that is poorly compliant and less likely to
tolerate acute aortic insufficiency versus one preconditioned by
the preoperative volume overload associated with significant pre-
existent regurgitation.
And, finally, could Dr Bonaros postulate why the RAI and PVL
in the current analysis were independent predictors of death
considering they are presumably related.
I would like to congratulate Dr Bonaros for an excellent presen-
tation and thank the Association for the privilege of discussing this
important work.
Dr Bonaros. Thank you, Dr Suri, for the excellent remarks. Just
brief answers to your questions.
Number one, the differences between the Sinning index and our
index; I think that both series have a series sample of a little bit
more than 100 patients. I think the Bonow group had 140 patients.
We had 110.gery c March 2014
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surements. This is a decision you reballoon this valve or even to
do a valve-in-valve. But, of course, it is a decision whereby you
can adjust your medical therapy for those patients to reduce the
afterload after the procedure on the ward or even ambulatory.
This is the first thing. And, of course, you don’t need any invasive
measurement with a catheter in the left ventricle or even
echocardiography.
For your second question, I agree with you that there is a very
huge difference if the patients had preexisting regurgitation or
this regurgitation happens acutely. So patients with preexisting
regurgitation, in other words with a pure aortic stenosis, who do
then have periprosthetic regurgitation, they would probably have
an impaired outcome. This is the major hypothesis of this study.
There was a very good article two years ago in American Heart
Journal entitled ‘‘Paravalvular Leakage from Pressure Overload to
Volume Overload.’’ So in this case, we have a volume overload in
the left ventricle, and this ventricle is not able to compensate for
this overload. So there should be some truth in this postulation.
For your third question,wewere also surprised to see that both the
index and the paravalvular regurgitation were independent predic-
tors. I, frankly, do not know the answer to the question. I can only
hypothesize that by using the frame of thevalve in the aortic annulus,
we change the geometry of the annulus, and of coursewe change the
compliance of the aortic root. Soprobably somepart of this so-called
windkessel function of the aortic root is not available anymore.
So probably there should be some correlation there, too, and
the question is what happens? What is the difference betweenThe Journal of Thoracic and Carthe two valve groups we have available for TAVI if a balloon-
expandable valve reacts in a different way than a self-expandable
valve.
Dr Lyle D. Joyce (Rochester, Minn). Are you using this to
change your practice as yet?
Dr Bonaros. To be honest, we have now started to take it into
consideration because we have now finished the evaluation. Again,
the numbers are limited. But we have started to take it into consid-
eration. The example I brought was the last patient we did last
week. We did take the RAI into consideration, yes.
Dr Joyce. Great. Thank you. Very nice presentation.
Dr Joseph J. Rubelowsky (Hattiesburg, Miss). When you
calculated your index, you got a preoperative value, and you sub-
tracted it from your postoperative value. Was there any preopera-
tive regurgitation, and would that influence what your index would
be as your final result?
Let’s say if you had aortic stenosis with a one- or two-plus aortic
regurgitation to begin with, and then you ended up with no aortic
stenosis and maybe one-plus paravalvular leak, would that influ-
ence what your index would be, I mean, when you predicted at
the end?
Dr Bonaros. You are absolutely right. So if you have preexist-
ing regurgitation, the subtrahend of the formula, is going to be
high.
So if the patient had a preexisting regurgitation grade 3 and ends
up a grade 2, he has an improved index. You are absolutely right.
But, fortunately, it was just two patients, so this would not affect
our results. That is a good point.diovascular Surgery c Volume 147, Number 3 1029
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FIGUREE1. Receiver operating characteristics (ROC) for relative ampli-
tude index (RAI) as predictor of 30-day mortality. CI, Confidence interval.
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FIGUREE2. Correlations between (A) RAI and PAR; (B) blood pressure amplitude (BPA) and PAR; and (C) diastolic blood pressure (DBP) and PAR.RAI,
Relative amplitude index; PAR, paravalvular aortic regurgitation; TAVI, transcatheter aortic valve implantation.
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